Sickness Evaluation at Altitude With Acetazolamide at Relative Doses

checkorphan
Learn more about:
Acute mountain sickness
Related Clinical Trial
Colorado-Oregon Altitude Study The Effects of Intermittent Hypoxia on Acute Hypoxic Injury Effect of Isocaloric Ketogenic Diet on Physical Performance at High Altitude The Pre-acclimatization Augmented Extreme Altitude Expedition Effect of Altitude on Iron Absorption in Iron Depleted Women Optimization Strategy for the Prevention of AMS by RIPC Combined With Acetazolamide Safety and Efficacy of T89 in the Prevention and Treatment of Adults With Acute Mountain Sickness (AMS) Effect of Acetazolamide on Right Heart Function at Rest in Lowlanders With COPD Traveling to High Altitude Acetazolamide to Prevent Impending Altitude-illness in Patients With COPD HIGH Altitude CArdiovascular REsearch Latin America Population Study Effect of Acetazolamide on Sleep Disordered Breathing in Lowlanders Older Than 40 Years at Altitude Effects of Melatonin on Sleep, Ventilatory Control and Cognition at Altitude. Effect of Acetazolamide on Lung Water Content by Ultrasound in Lowlanders Older Than 40 Years at Altitude Effect of Acetazolamide on Right Heart Function During Exercise in Lowlanders Older Than 40 Years at Altitude Effect of Acetazolamide on Visuo-motor Learning in Lowlanders Older Than 40 Years at Altitude Effect of Acetazolamide on Maximal Exercise Performance in Lowlanders Older Than 40 Years at Altitude Physiological Adaptations to Simulated Intermittent Altitude on Human Health and Performance Iron Status and Cardiopulmonary Physiology Effect of Acetazolamide on Right Heart Function at Rest in Lowlanders Older Than 40 Years at Altitude. Effect of Acetazolamide on Postural Control in Lowlanders Older Than 40 Years at Altitude Monitoring of the Cerebral Tissue Oxygenation and Perfusion in the Adapting Climber During Sleep in High Altitude The Psychophysiological Effect of Simulated and Terrestrial Altitude Relationship Between Succinate Dehydrogenase Mutations and High-Altitude Illness Cardio-respiratory Responses During Hypoxic Exercise in Individuals Born Prematurely Gut-microbiota Targeted Nutritional Intervention for Gut Barrier Integrity at High Altitude AZ, MZ, and the Pulmonary System Response to Hypoxia Study of the Effects of Iron Levels on the Lungs at High Altitude Effects of Aircraft Cabin Altitude on Passenger Comfort and Discomfort Three New Ideas to Protect Special Forces From the Stress of High Altitude Breathing Training to Improve Human Performance at High Altitude Oxidative Stress in Hypobaric Hypoxia Safety Evaluation of Aminophylline and Methazolamide Decompression Tables for Diving at Altitude Chronic Mountain Sickness, Systemic Vascular Function Evaluation of the Prevention and Treatment Effects of Chinese Medicine on High Altitude Illness Inhaled Budesonide for Altitude Illness Prevention Sickness Evaluation at Altitude With Acetazolamide at Relative Doses Prevention of Altitude Illness With Non-steroidal Anti-inflammatory Study (PAINS) Spectroscopic and Diffusion Weighted Analysis of the Effects of Dexamethasone on High Altitude Cerebral Oedema (HACE) Drug Combination on Exercise Performance at High Altitude Acclimatization Mechanisms During Ascent to 7500m Prevention of Acute Mountain Sickness by Intermittent Hypoxia Sickness Evaluation at Altitude With Acetazolamide at Relative Dosages Study Looking at End Expiratory Pressure for Altitude Illness Decrease (SLEEP-AID) Can Rhodiola Crenulata Intake Improve Oxygen Saturation and Decrease the Incidence of Acute Mountain Sickness Comparison of Metoclopramide and Ibuprofen for the Treatment of Acute Mountain Sickness A Trial of Acetazolamide Versus Placebo in Preventing Mountain Sickness During Rapid Ascent Training in Hypoxia to Prevent Acute Mountain Sickness Study of Compound Danshen Dripping Pills to Treat Acute Mountain Sickness Altitude Sickness Prevention With Ibuprofen Relative to Acetazolamide and Treatment Efficacy Controlled Hyperventilation as Prophylaxis for Acute Mountain Sickness Inhaled Budesonide and Acute Mountain Sickness Altitude Sickness Prevention and Efficacy of Comparative Treatments Alternative Treatments in Acute Mountain Sickness Effect of Acetazolamide on Acute Mountain Sickness in Lowlanders Older Than 40 Years Safety and Efficacy of T89 in Prevention and Treatment of Adults With Acute Mountain Sickness (AMS)

Brief Title

Sickness Evaluation at Altitude With Acetazolamide at Relative Doses

Official Title

Sickness Evaluation at Altitude With Acetazolamide at Relative Doses

Brief Summary

      The specific aim of this study is to evaluate whether acetazolamide 125mg daily is no worse
      than acetazolamide 250mg daily in decreasing the incidence of acute mountain sickness (AMS)
      in travelers to high altitude. The study population is hikers who are ascending at their own
      rate under their own power in a true hiking environment at the White Mountain Research
      Station, Owen Valley Lab (OVL) and Bancroft Station (BAR), Bancroft Peak, White Mountain,
      California

Detailed Description

      Acute mountain sickness (AMS) is a constellation of symptoms including headache, sleep
      disturbance, fatigue, dizziness, and nausea, vomiting, or anorexia that commonly occurs in
      travelers ascending to altitudes above 2,500m. AMS incidence varies based on altitude and
      ascent profile with rates reported from 25 to 75% in tourists, trekkers, and mountaineers at
      North American altitudes. Symptom onset is typically six to twelve hours after arrival at
      high altitude. This self-limited disease can be debilitating when severe, and left
      unrecognized or untreated may progress to potentially fatal high altitude cerebral edema
      (HACE). While gradual ascent has proven effective in preventing AMS, this approach is often
      impractical to recreationists, search and rescue, disaster relief, and military operations.

      Acetazolamide increases minute ventilation by 10-20% in subjects at altitude, and hastens
      acclimatization. It is well established that acetazolamide's main site of action is in the
      kidney, where it generates a metabolic acidosis through renal bicarbonate wasting and
      attenuates the effects of hypoxemic-induced respiratory alkalosis. Recommended dosing of
      acetazolamide for AMS prophylaxis has significantly decreased since early days of use in the
      1960s. The current recommended dose of acetazolamide for this indication is 125 mg twice
      daily, as opposed to historical recommendations of 500mg or 750mg daily. Multiple
      meta-analyses have concluded that when compared with higher doses, 250mg of acetazolamide
      daily has been shown to be equally efficacious, with the added benefit of decreasing side
      effects including paresthesias and dysgeusia. A randomized controlled trial confirmed
      effectiveness of acetazolamide 125mg twice daily in prevention of AMS when started prior to
      ascent. In this study, it was found that 125mg twice daily corresponded to a range of
      3-5mg/kg/day, depending on subject weight. Within this range, those on the lower dosing range
      did not have a greater incidence or severity of AMS. For subjects weighing between 50kg (110
      lbs) - 83kg (183 lbs), a dose of 250mg/day acetazolamide would fall in this range.
      Interestingly, mountaineers and trekkers have anecdotally reported protection against AMS
      with 125mg/day of acetazolamide, a dose below 3-5mg/kg for anyone over 41kg (91lb).

      Finding the lowest effective dose of acetazolamide for AMS prophylaxis is important because
      side effects of this medication can mimic AMS, decreasing the specificity of disease scoring
      on the validated Lake Louise Questionnaire (LLQ) and subsequent AMS diagnosis and
      chemoprophylactic effectiveness.Keeping in mind that LLQ is scored based on symptoms of
      headache, gastrointestinal symptoms, fatigue and weakness, and dizziness and lightheadedness,
      whatever effect acetazolamide has on AMS prevention may be obscured by its side effects that
      mimic the very same disease. Falsely positive LLQ scores in trekkers and mountaineers taking
      acetazolamide prophylaxis may lead to unnecessary pharmacologic treatment or even evacuation.
      From the perspective of high altitude research, participants randomized to or already taking
      acetazolamide may skew study results by decreasing LLQ specificity and potentially leading
      researchers to overestimate incidence of AMS.

Study Phase

Phase 1

Study Type

Interventional

Primary Outcome

Incidence of acute mountain sickness

Condition

Acute Mountain Sickness

Intervention

Acetazolamide Pill

Study Arms / Comparison Groups

 Acetazolamide 125mg twice daily
Description:  Acetazolamide pill 125mg twice daily by mouth, started the night prior to ascent and continued for 3 total doses

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status

Drug

Estimated Enrollment

108

Start Date

August 9, 2019

Completion Date

September 29, 2019

Primary Completion Date

September 29, 2019

Eligibility Criteria

        Inclusion Criteria:

          -  Able to complete moderate hike at altitude

          -  Live at elevation < 4,000 ft

          -  Able to arrange own transportation to study site

          -  Available for full study duration (Friday night - Sunday morning)

        Exclusion Criteria:

          -  Pregnancy

          -  Slept at altitude > 4,000 ft within 1 week of study

          -  Allergy to acetazolamide or sulfa drugs

          -  NSAIDs, acetazolamide, or corticosteroids within 48 hours prior to study start

          -  History of severe anemia, severe heart disease, advanced COPD/emphysema or sickle cell
             disease

Gender

All

Ages

18 Years - 75 Years

Accepts Healthy Volunteers

Accepts Healthy Volunteers

Contacts

Carrie Jurkiewicz, MD, ,

Location Countries

United States

Location Countries

United States

Administrative Informations

NCT ID

NCT03828474

Organization ID

49724

Responsible Party

Principal Investigator

Study Sponsor

Stanford University

Study Sponsor

Carrie Jurkiewicz, MD, Principal Investigator, Stanford University

Verification Date

February 2019